AI English summary of an SEC filing — figures as filed
Becton Dickinson BDXBecton Dickinson said that effective October 1, 2025, it reorganized its organizational units into five worldwide business segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. The company said the reorganization did not affect the principal product lines of any organizational unit.
Key points
AI summaryBecton Dickinson said that effective October 1, 2025, it reorganized its organizational units into five worldwide business segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. The company said the reorganization did not affect the principal product lines of any organizational unit.
Becton Dickinson said that on July 13, 2025 it entered into a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation. The company said that subsequent to the separation and combination, the Life Sciences segment will be eliminated from the company's segment reporting, which will consist of the remaining four reportable segments.
In recast historical segment data, the company presented total revenues for the 12 months ended September 30 of $21,840 million in 2025 and $20,178 million in 2024, with reported revenue change of 8.2% and currency-neutral change of 8.1%. The company said Life Sciences segment revenue was $3,296 million.
The company presented Connected Care revenue for the 12 months ended September 30 of $4,556 million in 2025 and $3,371 million in 2024, with reported change of 35.2%. Becton Dickinson said inorganic revenue adjustment for the segment was $977 million and cited Advanced Patient Monitoring as an acquisition.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Reorganization into five business segments effective October 1, 2025
Becton Dickinson said that effective October 1, 2025, it reorganized its organizational units into five worldwide business segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. The company said the reorganization did not affect the principal product lines of any organizational unit.
Source · Based on the filing body and exhibits
Agreement to combine Biosciences and Diagnostic Solutions business with Waters Corporation
Becton Dickinson said that on July 13, 2025 it entered into a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation. The company said that subsequent to the separation and combination, the Life Sciences segment will be eliminated from the company's segment reporting, which will consist of the remaining four reportable segments.
Source · Based on the filing body and exhibits
Annual total revenue $21,840 million, reported change 8.2%
In recast historical segment data, the company presented total revenues for the 12 months ended September 30 of $21,840 million in 2025 and $20,178 million in 2024, with reported revenue change of 8.2% and currency-neutral change of 8.1%. The company said Life Sciences segment revenue was $3,296 million.
Source · Based on the filing body and exhibits
Connected Care annual revenue $4,556 million and Advanced Patient Monitoring
The company presented Connected Care revenue for the 12 months ended September 30 of $4,556 million in 2025 and $3,371 million in 2024, with reported change of 35.2%. Becton Dickinson said inorganic revenue adjustment for the segment was $977 million and cited Advanced Patient Monitoring as an acquisition.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…